SUPN

SUPN

USD

Supernus Pharmaceuticals Inc. Common Stock

$57.000+1.570 (2.832%)

Preço em tempo real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$55.430

Máximo

$57.400

Mínimo

$54.610

Volume

4.00M

Fundamentos da empresa

Capitalização de mercado

3.2B

Setor

Drug Manufacturers - Specialty & Generic

País

United States

Estatísticas de negociação

Volume médio

0.82M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $29.16Atual $57.000Máximo $57.65

Notícias relacionadas

Analyst Upgrades

B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals with a Buy rating and announces Price Target of $65.

Ver mais
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
Analyst Upgrades

TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals with a Buy and raises the price target from $45 to $60.

Ver mais
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

Ver mais
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Analyst Upgrades

Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals from Neutral to Overweight and raises the price target from $40 to $65.

Ver mais
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.